Abstract | OBJECTIVES: METHODS: One hundred seventy-six patients with necrotizing pancreatitis were prospectively randomized to prophylactic treatment with 0.5 g meropenem t.i.d. intravenously or 0.5 g imipenem q.i.d. intravenously. The occurrence of infection of pancreatic necrosis, rate of extrapancreatic infections, systemic and local complications, need for surgery, mortality rate, and length of hospitalization were recorded for each group. When a septic complication of pancreatic necrosis was suspected, fine needle aspiration with cultures of the sample was performed. Surgery was performed in cases of verified infected necrosis. CONCLUSION: No difference was observed between patients treated with meropenem and those treated with imipenem in terms of incidence of pancreatic infection (11.4% versus 13.6%) and extrapancreatic infections (21.6% versus 23.9%) and clinical outcome. Meropenem is as effective as imipenem in preventing septic complications of patients with severe acute pancreatitis.
|
Authors | Gianpiero Manes, Pier Giorgio Rabitti, Antonella Menchise, Elisabetta Riccio, Antonio Balzano, Generoso Uomo |
Journal | Pancreas
(Pancreas)
Vol. 27
Issue 4
Pg. e79-83
(Nov 2003)
ISSN: 1536-4828 [Electronic] United States |
PMID | 14576501
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Thienamycins
- Imipenem
- Meropenem
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents
(therapeutic use)
- Bacteria
(drug effects, isolation & purification)
- Female
- Humans
- Imipenem
(therapeutic use)
- Male
- Meropenem
- Middle Aged
- Pancreatitis, Acute Necrotizing
(complications)
- Prospective Studies
- Sepsis
(complications, microbiology, prevention & control)
- Thienamycins
(therapeutic use)
- Time Factors
- Treatment Outcome
|